Tirzepatide vs Retatrutide
Tirzepatide and retatrutide represent successive generations of incretin therapy — a dual agonist that is already approved versus a triple agonist still in development. Retatrutide adds glucagon-receptor activity to the GIP/GLP-1 mechanism, which early trials suggest may push weight loss even further. This comparison contrasts an approved medicine with an investigational one.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Class | Dual GIP and GLP-1 receptor agonist | Triple GIP, GLP-1, and glucagon receptor agonist |
| Primary mechanism | Combined GIP + GLP-1 incretin action on appetite and glucose | Adds glucagon-receptor activity, which may raise energy expenditure on top of incretin effects |
| Regulatory status | FDA-approved (Mounjaro, Zepbound) | Investigational; not approved — still in clinical trials |
| Reported weight loss (trials) | Up to ~21% at the top dose over ~72 weeks (SURMOUNT program) | ~24% at the highest dose over 48 weeks in a phase 2 trial |
| Reported dosing / titration | Titrated from 2.5 mg up to 15 mg weekly | Trial doses titrated up to ~12 mg weekly (investigational) |
| Route / frequency | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (in trials) |
| Evidence base | Multiple completed phase 3 trials; approved and marketed | Phase 2 complete, phase 3 ongoing; no approval yet |
| Best studied for | Type 2 diabetes and weight management (approved uses) | Investigational obesity and metabolic research |
Tirzepatide
Tirzepatide is an approved dual GIP/GLP-1 agonist (Mounjaro, Zepbound) with completed phase 3 trials and average weight loss up to about 21%.
Full Tirzepatide profile →Retatrutide
Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon) that added glucagon-driven energy expenditure and reached about 24% weight loss in a phase 2 trial, but it is not approved.
Full Retatrutide profile →The bottom line
Early trial data suggest retatrutide’s triple-agonist mechanism may drive even greater weight loss than tirzepatide, but retatrutide remains investigational and is not approved for any use, while tirzepatide is an approved medicine. Cross-trial percentages are not a substitute for head-to-head data, and only a completed phase 3 program and regulatory review can establish retatrutide’s place. This is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
Tirzepatide vs Retatrutide FAQ
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual agonist that activates the GIP and GLP-1 receptors, while retatrutide is a triple agonist that also activates the glucagon receptor. The added glucagon activity is thought to increase energy expenditure, and early trials show numerically greater weight loss, but retatrutide is still experimental.
Is retatrutide approved?
No. Retatrutide is investigational and has not been approved by the FDA or other regulators for any use; it is still in clinical trials. Tirzepatide, by contrast, is approved as Mounjaro and Zepbound.
Is retatrutide more effective than tirzepatide for weight loss?
In separate trials retatrutide reached about 24% weight loss versus up to about 21% for tirzepatide, but these come from different studies rather than a direct head-to-head comparison, and retatrutide is not yet approved. It is too early to draw firm conclusions — this is not medical advice.
Are tirzepatide and retatrutide the same kind of drug?
Both belong to the incretin-based class of metabolic peptides and are once-weekly injectables in research, but tirzepatide hits two receptors and is approved, whereas retatrutide hits three and remains investigational.